Phase 4
Completed N=14
Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
Source: ClinicalTrials.gov NCT02893293 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcomePrimary: Signal to Noise Ratio (SNR) — 33.82; 129.56 dB — p=0.002
◆ Published Evidence
Established
27citations · ~3 / year
Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof-of-Concept Study in Patients.
Summary
The goal of the project is to evaluate osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI.
Linked Publications
-
Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof-of-Concept Study in Patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Signal to Noise Ratio (SNR) |
33.82; 129.56 | 0.002 sig |
| PRIMARY T2*-Relaxation Time |
9.04; 13.7 | 0.02 sig |
| PRIMARY Evaluation of Treatment Response to Decompression Surgery and Stem Cell Transplant |
12 | — |
Eligibility Criteria
Inclusion Criteria
- Osteonecrosis
- planned decompression surgery with autologous stem cell transplant
Exclusion Criteria
- Contraindications for magnetic resonance imaging
- Hemosiderosis/hemochromatosis ( patients can still be included in the non-ferumoxytol arm)
Data sourced from ClinicalTrials.gov (NCT02893293) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.